Eisspeedway

Polar surface area

Electrical potential surface of paracetamol showing polar areas in red and blue

The polar surface area (PSA) or topological polar surface area (TPSA) of a molecule is defined as the surface sum over all polar atoms or molecules, primarily oxygen and nitrogen, also including their attached hydrogen atoms.

PSA is a commonly used medicinal chemistry metric for the optimization of a drug's ability to permeate cells. Molecules with a polar surface area of greater than 140 angstroms squared (Å2) tend to be poor at permeating cell membranes.[1] For molecules to penetrate the blood–brain barrier (and thus act on receptors in the central nervous system), a PSA less than 90 Å2 is usually needed.[2]

TPSA is a valuable tool in drug discovery and development. By analyzing a drug candidate's TPSA, scientists can predict its potential for oral bioavailability and ability to reach target sites within the body. This prediction hinges on a drug's ability to permeate biological barriers.

Permeating these barriers, such as the Blood-Brain Barrier (BBB), the Placental Barrier (PB), and the Blood-Mammary Barrier (BM), is crucial for many drugs to reach their intended targets.

The BBB, for example, protects the brain from harmful substances. Drugs with a lower TPSA (generally below 90 Ų) tend to permeate the BBB more easily, allowing them to reach the brain and exert their therapeutic effects (Shityakov et al[3]., 2013).

Similarly, for drugs intended to treat the fetus, a lower TPSA (below 60 Ų) is preferred to ensure they can pass through the placenta (Augustiño-Roubina[4] et al., 2019).

Breastfeeding mothers also need consideration. Here, an optimal TPSA for a drug is around 60-80 Ų to allow it to reach the breast tissue for milk production, while drugs exceeding 90 Ų are less likely to permeate the Blood-Mammary Barrier.[5]

See also

References

  1. ^ Pajouhesh H, Lenz GR (Oct 2005). "Medicinal Chemical Properties of Successful Central Nervous System Drugs". NeuroRx. 2 (4): 541–553. doi:10.1602/neurorx.2.4.541. PMC 1201314. PMID 16489364.
  2. ^ Hitchcock SA, Pennington LD (May 2006). "Structure - Brain Exposure Relationships". J. Med. Chem. 49 (26): 7559–7583. doi:10.1021/jm060642i. PMID 17181137.
  3. ^ Shityakov, Sergey; Neuhaus, Winfried; Dandekar, Thomas; Förster, Carola (2013). "Analysing molecular polar surface descriptors to predict blood-brain barrier permeation". International Journal of Computational Biology and Drug Design. 6 (1–2): 146–156. doi:10.1504/IJCBDD.2013.052195. ISSN 1756-0756. PMID 23428480.
  4. ^ Hester, Gabrielle; Lang, Tom; Madsen, Laura; Tambyraja, Rabindra; Zenker, Paul (January 2019). "Timely Data for Targeted Quality Improvement Interventions: Use of a Visual Analytics Dashboard for Bronchiolitis". Applied Clinical Informatics. 10 (1): 168–174. doi:10.1055/s-0039-1679868. ISSN 1869-0327. PMC 6402943. PMID 30841007.
  5. ^ "Δραστική: PARACETAMOL". farmako.net. Retrieved 2024-04-10.

Literature